Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas

Pathobiology

Volumn 78, Issue 3, 2011, Pages 171-180

  Funayama, Akinori ^a   Cheng, Jun ^a   Maruyama, Satoshi ^b   Yamazaki, Manabu ^a   Kobayashi, Takanori ^b   Syafriadi, Mei ^a   Kundu, Sukalyan ^a   Shingaki, Susumu ^a   Saito, Chikara ^a   Saku, Takashi ^a,b  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

Author keywords

Carcinoma in situ; D2 40; Epithelial dysplasia; Oral mucosa; Podoplanin; Squamous cell carcinoma

Indexed keywords

PODOPLANIN;

ARTICLE; CANCER GRADING; CARCINOMA IN SITU; EPITHELIUM DYSPLASIA; EPITHELIUM HYPERPLASIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUTH CARCINOMA; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CARCINOMA IN SITU; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MEMBRANE GLYCOPROTEINS; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM STAGING; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 79958063205     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000324926     Document Type: Article

References (26)

1. Franceschi S, Bodoli E, Herrero R, Muñoz N: Comparison of cancers of the oral cavity and pharynx worldwide: etiological clues. Oral Oncol 2000;36:106-115.
2. Statistic and Information Department, the Minister's Secretariat, Ministry of Health, Labour and Welfare, Japan, Health and Welfare Statistics Association: Vital Statistics of Japan 2006. Tokyo, Yamatosogo Publishing, 2006, pp 270-275.
3. Gale N, Piclch BZ, Sidransky D, El Naggar A, Westra W, Califano J, Johnson N, MacDonald DG: Epithelial precursor lesions; in Barnes L, Evson JW, Reichart P, Sidransky D (eds): Pathology and Genetics of Head and Neck Tumours. World Health Organization Classification of Tumours. Lyon, IARC Press, 2005, pp 177-179.
4. Pindborg JJ, Reichart PA, Smith CJ, van der Waal I: Squamous epithelial dysplasia: Histological typing of cancer and precancer of the oral mucosa; in Pindborg JJ, Reichart PA, Smith CJ, van der Waal I (eds): World Health Organization International Histological Classification of Tumours. Berlin, Springer, 1997, pp 24-26.
5. Wahi PN, Cohen B, Luthra UK, Torloni H: Histological typing of oral and oropharyngeal tumours; in Wahi PN, Cohen B, Luthra UK, Torloni H (eds): International Histological Classification of Tumours. Geneva, World Health Organization, 1971, pp 19, 23.
6. Kobayashi T, Maruyama S, Cheng J, Ida-Yonemochi H, Yagi M, Takagi R, Saku T: Histopathological varieties of oral carcinoma in situ: diagnosis aided by immunohistochemistry dealing with the second basal cell layer as the proliferating center of oral mucosal epithelia. Pathol Int 2010;60:156-166.
7. Takeda T, Sugihara K, Hirayama Y, Hirano M, Tanuma JI, Semba I: Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med 2006;35:369-375. (Pubitemid 43880174)
8. Eriksen JG, Steiniche T, Sogaard H, Overgaard J: Expression of integrins and Ecadherin in squamous cell carcinomas of the head and neck. APMIS 2004;112:560-568. (Pubitemid 40040183)
9. Alvarado CG, Maruyama S, Cheng J, Ida-Yonemochi H, Kobayashi T, Yamazaki M, Takagi R, Saku T: Nuclear translocation of ß-catenin synchronized with loss of E-cad-herin in oral epithelial dysplasia with a characteristic two-phase appearance. Histopathology, in press.
10. Ikarashi T, Ida-Yonemochi H, Ohshiro K, Cheng J, Saku T: Intraepithelial expression of perlecan, a basement membrane-type heparan sulfate proteoglycan reflects dysplastic changes of the oral mucosal epithelium. J Oral Pathol Med 2004;33:87-95. (Pubitemid 38166427)
11. Tilakaratne WM, Kobayashi T, Ida-Yonemochi H, Swelam W, Yamazaki M, Mikami T, Alvarado CG, Shahidul AM, Maruyama S, Cheng J, Saku T: Matrix metalloproteinase 7 and perlecan in oral epithelial dysplasia and carcinoma in situ: an aid for histopathologic recognition of their cell proliferation centers. J Oral Pathol Med 2009; 38: 348-355.
12. Marks A, Sutherland DR, Bailey D, Iglesias J, Law J, Lei M, Yeger H, Banerjee D, Baumal R: Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-578. (Pubitemid 29213215)
13. Evangelou E, Kyzas PA, Trikalinos TA: Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach. Mod Pathol 2005;18:1490-1497. (Pubitemid 41509404)
14. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K, Kerjaschki D: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385-394. (Pubitemid 29094089)
15. Saad RS, Kordunsky L, Liu YL, Denning KL, Kandil HA, Silverman JF: Lymphatic microvessel density as prognostic marker in colorectal cancer. Mod Pathol 2006; 19:1317-1323. (Pubitemid 44423078)
16. Kundu S, Cheng J, Maruyama S, Suzuki M, Kawashima H, Saku T: Lymphatic involvement in the histopathogenesis of mucous retention cyst. Pathol Res Pract 2007;203:89-97. (Pubitemid 46173163)
17. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005; 166:913-921. (Pubitemid 40315647)
18. Dumoff KL, Chu C, Xu X, Pasha T, Zhang PJ, Acs G: Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol 2005;18:97-104. (Pubitemid 40128101)
19. Dumoff KL, Chu CS, Harris EE, Holtz D, Xu X, Zhang PJ, Acs G: Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol 2006; 19: 708-716.
20. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, Quintanilla M: Characterization of human PA2.26 antigen (Tlalpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005;113:899-910. (Pubitemid 40096869)
21. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006; 107: 563-569. (Pubitemid 44107217)
22. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, Lee JJ, Kim E, Hong WK, Lippman SM, Mao L: Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008;26:354-360. (Pubitemid 351171684)
23. Syafriadi M, Cheng J, Jen KY, Ida-Yonemochi H, Suzuki M, Saku T: Two-phase appearance of oral epithelial dysplasia resulting from focal proliferation of parabasal cells and apop-tosis of prickle cells. J Oral Pathol Med 2005; 34:140-149. (Pubitemid 40293222)
24. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M: Enhanced expression of Aggrus (Tlalpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumor Biol 2005;26:195-200. (Pubitemid 41379745)
25. Gandarillas A, Scholl FG, Benito N, Gamalllo C, Quintanilla M: Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog 1997; 20:10-18. (Pubitemid 27461534)
26. Martin-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S, Quintanilla M: Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci 2006;119:4541-4553. (Pubitemid 44830653)